A revolution in urological holmium lasers and fibers
YOKNEAM, Israel, March 22, 2017 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announces the upcoming launch of its new Moses™ holmium technology in a range of launch events at the 32nd annual European Association of Urology (EAU) Congress, taking place in London from March 24-27, 2017.
Moses™ is a new breakthrough patent pending technology that redefines holmium lithotripsy technology as it exists today. The unique Moses technology is designed to significantly reduce retropulsion during lithotripsy, enabling less stone migration and a more efficient procedure. Moses™ technology includes a proprietary combination of holmium lasers and fibers that optimize holmium energy transmission allowing the surgeon more control regardless of the working distance between the fiber and the stone. The Moses™ tailored premium fiber range of 200, 365, and 550 D/F/L is designed for optimal energy transmission and durability. Additionally, the Moses™ 200 D/F/L fiber allows surgeons to treat stones in difficult to reach locations, and enables smooth initial fiber insertion through a fully deflected scope.
Moses™ initial clinical experience was conducted by Prof. Mostafa Elhilali of McGill University Health Center Department of Urology in Montreal, Canada, a leading global expert in the field of urology. As part of the EAU Annual Congress scientific program, Prof. Elhilali will present his findings onsite in a poster presentation and in a dedicated workshop hosted by Lumenis. The clinical experience confirms that Moses™’ unique capabilities provide surgeons with better control during holmium lithotripsy procedures, including stone dusting and stone fragmentation. The data obtained shows a significant reduction in stone retropulsion that may lead to a reduction in stone migration and more efficient lithotripsy procedures.
“My experience with the Moses™ technology shows that it is a true breakthrough in holmium laser lithotripsy, demonstrating enhanced accessibility and significant reduction in retropulsion,” said Prof. Elhilali. “I am keen to continue my clinical work and further explore the potential procedural efficiency of the Moses™ technology.”
“Lumenis is excited to introduce this next generation, breakthrough technology that will revolutionize the world of holmium laser lithotripsy,” said Tzipi Ozer-Armon, CEO of Lumenis. “The invention of Moses™ is a culmination of over 20 years of experience in holmium lasers and our corporate commitment to science and innovation. To date, we have proudly offered industry-leading solutions for patients affected by urinary stones worldwide and look forward to the opportunity to explore clinical outcomes at the next level.”
Moses™ is also being evaluated further by additional leading global experts including Dr. Andrew Symes, Consultant Urological Surgeon, Brighton & Sussex University Hospital NHS Trust, UK, who noted: “The Moses™ technology provides a greater sense of control due to minimized retropulsion. This is particularly valuable when dusting large stones in the kidney, but also when dealing with upper ureteric stones.”
During the EAU Annual Congress, Lumenis will offer a wide range of launch activities, enabling participants to get a first-hand experience of the new technology:
- Moses™ Poster Presentation - Prof. Mostafa Elhilali (Canada)
Evaluation of the new Moses™ Technology of holmium laser lithotripsy: Initial clinical experience.
Saturday March 25th 2017, 14:15 – 15:45 (Room London, North Hall, Level 1) - Moses™ Launch Cocktail Reception
Learn about the new technology from leading experts over a glass of prosecco and canapés
Sunday March 26th 2017, 17:00 – 17:30 (Lumenis booth G34) - Lumenis Industry Workshop – “Revealing Moses™, Revolutionary New Holmium Technology” - Prof. M Elhilali (Canada), Mr. Mark Cynk (UK), Mr. Tim Larner (UK),
A thorough introduction of the new Moses™ Technology and its advantages in laser lithotripsy. Additional overview of advanced BPH techniques
Sunday March 26th 2017, 17:45-19:15 (Room 9, Capital Suite, Level 3)
In addition, Lumenis booth G34 will host a variety of booth talks and live surgeries:
Saturday, March 25th 2017
- Mr. Mark Cynk – High Power for Enucleation (Booth G34, 13:00 – 13:30)
- Mr. Tim Larner – Xpeeda™ Holmium Vaporization (Booth G34, 14:00 – 14:30)
- Mr. Rick Popert – Live HoLEP Surgery – Part III– Guy’s Hospital – (eURO-Auditorium, 14:25 – 14:40)
- Mr. Mark Cynk – High Power for Enucleation (Booth G34, 15:30 – 16:00)
- Mr. Tim Larner – Pre-recorded Xpeeda Holmium Vaporization (eURO-Auditorium, 16:45 – 16:55)
- Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 17:00 – 17:30)
Sunday, March 26th 2017
- Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 11:00 – 11:30)
- Dr. Oleg Burlaka – Russian Market HoLEP Presentation (Booth G34, 12:00 – 12:30)
- Mr. Tim Larner – Xpeeda Vaporization (Booth G34, 15:00 – 15:30)
Monday, March 27th 2017
- Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 11:00 – 11:30)
- Prof. Mostafa Elhilali – Moses™ Breakthrough Technology (Booth G34, 13:00 – 13:30)
About Lumenis
www.lumenis.com
Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.